BofA raised the firm’s price target on Edwards Lifesciences (EW) to $82 from $75 and keeps a Neutral rating on the shares. While stating that the path forward “seems more favorable” post the company’s analyst day and new guidance, the firm reiterates a Neutral rating as it thinks that the PE multiple already reflects Edwards’ growth outlook. However, as long as Edwards can execute against this new guidance, the firm thinks that “interest will build over 2025 into moderate data at TCT 2026,” the analyst added.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $75 from $70 at TD Cowen
- Edwards Lifesciences price target raised to $68 from $63 at Canaccord
- Early notable gainers among liquid option names on December 4th
- Edwards Lifesciences sees FY25 adjusted EPS $2.40-$2.50, consensus $2.47
- Edwards Lifesciences backs FY24 constant currency sales growth of 8%-10%